Extracorporeal blood purification in severe liver failure with the albumin dialysis MARS® - Impact on relevant intensive care parameters;Extrakorporale blutreinigung im schweren leber-versaqen mit der albumindialyse MARS® - Einfluss auf intensivmedizinisch relevante parameter

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 40, Issue 4, 2005, Pages 199-206

  Mitzner, Steffen ^a   Klammt, S ^a   Stange, J ^a   Noldge Schombyrg C F E ^a   Schmidt, R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Albumin; Albumin dialysis; Bile acids; Bilirubin; Hepatic failure; Liver support methods

Indexed keywords

ALBUMIN; ANTITHROMBIN III; BILE ACID; BILIRUBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; CHOLINESTERASE; CREATININE; PROTHROMBIN; SERUM ALBUMIN;

ADSORPTION; BIOCOMPATIBILITY; BRAIN FUNCTION; DIALYSIS; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; REVIEW; TREATMENT OUTCOME; ACUTE KIDNEY FAILURE; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; COST BENEFIT ANALYSIS; DRUG CONTRAINDICATION; HEMODYNAMICS; INSTRUMENTATION; LIVER FUNCTION TEST; METHODOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

BILE ACIDS AND SALTS; BILIRUBIN; COST-BENEFIT ANALYSIS; HEMODYNAMIC PROCESSES; HUMANS; INTENSIVE CARE; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; LIVER FAILURE; LIVER FUNCTION TESTS; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 17144424935     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826116     Document Type: Review

References (62)

1. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001; 34: 447-455
2. Awad SS, Sawada S, Soldes OS, Rich PB, Klein R, Alarcon WH, Wang SC, Bartlett RH. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999; 45: 47-49
3. Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase 1 trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-362
4. Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. Role of MARS in patients suffering from hypoxic liver failure following cardiogenic shock after cardiac surgery (Abstract). J Hepatol 2003; 38 (Suppl 2): 35
5. Campli CD, Gaspari R, Mignani V, Stifano G, Santoliquido A, Verme LZ, Proietti R, Pola P, Silveri NG, Gasbarrini G, Gasbarrini A. Successful MARS treatment in severe cholestatic patients with acute on chronic liver failure. Artif Organs 2003; 27: 565-569
6. Catalina MV, Barrio J, Anaya F, Salcedo M, Rincon D, Clemente G, Banares R. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Internat 2003; 23 (Suppl 3): 39-43
7. Chen S, Zhang L, Shi Y, Yang X, Wang M. Molecular adsorbent recirculating system: clinical experience in patients with liver failure based on hepatitis B in China. Liver 2002; 22 (Suppl 2): 48-51
8. Covic A, Goldsmith DJ, Gusbeth-Tatomir P, Volovat C, Dimitriu AG, Cristogel F, Bizo A. Successful use of Molecular Adsorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver Internat 2003; 23 (Suppl 3): 21-27
9. Davenport S. Artificial hepatic support: where are we now? Blood Purif 2001; 19: 1-3
10. Doria C, Mandala L, Smith J, Vitale CH, Lauro A, Gruttadauria S, Marino IR, Foglieni CS, Magnone M, Scott VL. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9: 437-443
11. Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, Zhang WY, Lu LH, Guo X, Sun FX, Zhang HY, Liu XD, Zhang JP, Yao Y, He ZP, Wang MM. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Internat 2003; 23 (Suppl 3): 16-20
12. Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs. Liver Internat 2003; 23 (Suppl 3): 61-65
13. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-958
14. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Internat 2003; 23 Suppl 3: 66-72
15. Hommann M, Kasakow LB, Geoghegan J, Kornberg A, Schotte U, Fuchs D, Hermann J, Zintl F, Scheele J. Application of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month-old child. Pediatr. Tranplant 2002; 6: 340-343
16. Huster D, Schubert C, Berr F, Mossner J, Caca K. Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J Hepatol 2002; 37: 413-414
17. Ichai P, Samuel D. Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis? J Hepatol 2003; 38: 104-106
18. Isoniemi H. Current indications for albumin dialysis: Acute hepatic failure. 4th International Symposium on Albumin Dialysis in Liver Disease, 6.-8. September 2002, Book of Abstracts. Rostock: 2002; 21
19. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 24-31
20. Javouhey E, Collard L, Cochat P, Floret D. Bridge to liver transplantation using extracorporeal albumin dialysis: preliminary results in children (Abstract). Pediatr Transplant 2003; 7 (Suppl 4): 121
21. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
22. Kiley JE, Welch HF, Pender JC, Welch CS. Removal of blood ammonia by hemodialysis. Proc Soc Exp Biol Med 1956; 91: 489-490
23. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289: 217-222
24. Klammt S, Stange J, Mitzner SR, Peszynski P, Peters E, Liebe S. Extracorporeal liver support by recirculating albumin dialysis: analysing the effect of the first clinically used generation of the MARSystem. Liver 2002; 22 (Suppl 2): 30-34
25. Koivusalo AM, Yildirim Y, Vakkuri A, Lindgren L, Hockerstedt K, Isoniemi H. Experience with albumin dialysis in five patients with severe overdoses of paracetamol. Acta Anaesthesiol Scand 2003; 47: 1145-1150
26. Kramer L, Gendo A, Madl C, Ferrara I, Funk G, Schenk P, Sunder-Plassmann G, Hörl WH. Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis 2000; 36: 1193-1200
27. Loock J, Treichel U, Gerken G, Malago M, Broelsch CE, Phillip T, Heemann U. Treatment of split-liver recipients with poor graft function by albumin dialysis (MARS). Z Gastroenterol 2001; 39 (Suppl 2): 18
28. Manz T, Ochs A, Bisse E, Strey C, Grotz W. Liver support - a task for nephrologists? Extracorporeal treatment of a patient with fulminant Wilson crisis. Blood Purif 2003; 21: 232-236
29. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. Clin Nephrol 2002; 58: 376-383
30. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Use of albumin dialysis in the treatment of hepatic and renal dysfunction due to paracetamol intoxication. Nephrol Dial Transplant 2002; 17: 316-317
31. Mitzner S, Stange J. Cell-free artificial liver support: a critical review. In: Körner MM, Körfer R (eds). Current aspects and concepts of nursing, coordinating, bridging and rehabilitation in organ transplantation. Amsterdam: Elsevier, 1995: 81-88
32. Mitzner S, Stange J, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Henschel J, Schulz M, Lohr M, Liebe S, Schareck W, Hopt UT. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286
33. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R. Albumin dialysis using the molecular adsorbent recirculating system. Curr Opin Nephrol Hypertens 2001; 10: 777-783
34. Mitzner S, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Amer Soc Nephrol 2001; 12 (Suppl 17): S75-S82
35. Mitzner S, Loock J, Peszynski P, Klammt S, Majcher-Peszynska J, Gramowski A, Stange J, Schmidt R. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS - a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002; 17: 463-475
36. Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. Hepatol Res 2003; 25: 442-446
37. Novelli G, Rossi M, Pretagostini R, Novelli L, Poli L, Ferretti G, Iappelli M, Berloco P, Cortesini R. A 3-year experience with Molecular Adsorbent Recirculating System (MARS): our results on 63 patients with hepatic failure and color doppler US evaluation of cerebral perfusion. Liver Internat 2003; 23 (Suppl 3): 10-15
38. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186-1192
39. Pares A, Cisneros L, Salmeron JM, Mas A, Torras A, Caballeria J, Rodes J. The Molecular Adsorbent Recirculating System (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis. J Hepatol 2002; 36 (Suppl 1): 541
40. Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Amer J Gastroenterol 2004; 99: 1105-1110
41. Peszynski P, Klammt S, Peters E, Mitzner S, Stange J, Schmidt R. Albumin dialysis: Single pass vs. recirculation (MARS). Liver 2002; 22 (Suppl 2): 40-42
42. Prokurat S, Grenda R, Lipowski D, Kalicinski P, Migdal M. MARS procedure as a bridge to combined liver-kidney transplantation in severe chromium-copper acute intoxication: a paediatric case report. Liver 2002; 22 (Suppl 2): 76-77
43. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D. Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984-990
44. Schachschal G, Morgera S, Kupferling S, Schmidt HH, Lochs H. MARS dialysis in the state of chronic rejection in a liver transplant recipient. Am J Gastroenterol 2002; 97: 1059-1060
45. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 709-712
46. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7: 1034-1039
47. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the Molecular Adsorbents Recirculating System in patients with hyperacute liver failure: a prospective, controlled trial. Liver Transpl 2003; 9: 290-297
48. Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, Williams R, Jalan R. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transpl 2002; 8: 962-967
49. Sen S, Mookerjee RP, Davies NA, Williams R, Jalan R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther 2002; 16 (Suppl 5): 32-38
50. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22 (Suppl 2): 5-13
51. Sen S, Ratnaraj N, Davies NA, Mookerjee RP, Cooper CE, Patsalos PN, Williams R, Jalan R. Treatment of phenytoin toxicity by the Molecular Adsorbents Recirculating System (MARS). Epilepsia 2003; 44: 265-267
52. Sen S, Rose C, Ytrebo LM, Davies NA, Nedredal GI, Drevland SS, Kjonno M, Williams R, Butterworth R, Revhaug A, Jalan R. Albumin dialysis reduces brain water and intracranial pressure in acute liver failure: a randomized controlled study in a pig model (Abstract). Hepatology 2003; 34 (Suppl 1): 540A
53. Siewert-Delle A, Henriksson BA, Backman L. Albumin dialysis with the MARS (Molecular adsorbent Recirculating system) for a patient with acute liver failure due to paracetamol intoxication: a case report. (Abstract). Z Gastroenterol 2001; 39 (Suppl 2): 48
54. Sorkine P, Ben Abraham R, Szold O. Liver support systems. In: Vincent JL (ed). 2001 Yearbook of intensive care and emergency medicine. Berlin: Springer, 2001: 619-627
55. Sorkine P, Ben Abraham R, Szold O, Biderman P, Kidron A, Merchav H, Brill S, Oren R. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001; 29: 1332-1336
56. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993; 39: M621-M625
57. Stange J, Mitzner S, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Hentschel J, Schulz M, Löhr M, Liebe S, Schareck W, Hopt UT. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000; 6: 603-613
58. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002; 22 (Suppl 2): 20-25
59. Stockmann HB, Hiemstra CA, Marquet RL, Ijzermans JNM. Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg 2000; 231: 460-470
60. Voiculescu M, Ioanitescu S, Rusu E, Micu D, Mihaila M, Micu L. Successful application of MARS therapy in a 7 year-old patient with hepatic chronic rejection and severe cholestatic syndrome. Rom J Gastroenterol 2002; 11: 135-140
61. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001; 34: 255-261
62. Zakaria N, Wendon J, Creamer D, Heaton N, Devlin J. Albumin dialysis (MARS device) relieves cholestatic pruritus in a dramatic but non-sustained manner. Hepatology 2001; 34: 550A